Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I, single arm, open-label trial that will utilise a Time To Event Continual
Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in
combination with concurrent CRT in NSCLC. Twenty evaluable participants will be recruited at
two centres.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oxford
Collaborators:
Cancer Research UK National Institute for Health Research, United Kingdom NHS Lothian NHS Research Scotland Oxford University Hospitals NHS Trust